Answers are grounded in this paper and cite their sources.
Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening hyperinflammatory syndrome characterized by uncontrolled activation of macrophages and lymphocytes, resulting in a cytokine storm, multiorgan dysfunction, and substantial mortality despite appropriate treatment.In adults, HLH is most commonly secondary to infections, malignancies, or autoimmune disorders.Less common but increasingly recognized triggers include drug-induced and iatrogenic causes, as well as severe cutaneous adverse reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS).The spectrum of infectious triggers varies with geographic exposure, and visceral leishmaniasis, a recognized but uncommon trigger of secondary HLH, may therefore present a considerable diagnostic challenge in non-endemic regions, particularly in immunocompromised patients.We present the case of a 68-year-old man with relapsing-remitting multiple sclerosis who was receiving fingolimod and presented with persistent high-grade fever, progressive weakness, bicytopenia, transaminitis, and splenomegaly.Despite extensive microbiological, serological, radiological, and histopathological investigations, the underlying cause remained elusive.The clinical, histopathological, and laboratory findings, including extreme hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, and cytopenias, fulfilled 6 of 8 HLH-2004 diagnostic criteria, yielding an HScore of 292 and a probability of greater than 99% for reactive HLH.Immunosuppressive therapy was initiated because of impending organ failure.Splenectomy, indicated by splenic necrosis, provided the diagnostic specimen.Ultimately, polymerase chain reaction (PCR) testing of splenic tissue and bone marrow established the diagnosis of visceral leishmaniasis.Targeted treatment with liposomal amphotericin B resulted in sustained clinical recovery, with no evidence of recurrence over 7.5 years of follow-up.This case highlights the importance of considering HLH in patients with fever of unknown origin and cytopenias, particularly when receiving immunomodulatory therapy.Furthermore, it illustrates the diagnostic challenges associated with visceral leishmaniasis in non-endemic regions and raises the possibility that fingolimod-induced immune modulation increases the risk of opportunistic infections and disease reactivation.
No takes yet. Share an insight, caveat, or question.
Wypasek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: